Synapse - Department of Medicine

Results (39719)

ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)

Meeting Abstract

Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

SVR (spleen volume reduction) predicts OS (overall survival) in MF (myelofibrosis) patients on PAC (pacritinib) but not BAT (best available therapy): PERSIST-2 landmark OS analysis

Meeting Abstract

Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Preliminary data from the phase 1/2 study of TP-3654, an investigational selective PIM1 kinase inhibitor, showed cytokine reduction and clinical responses in relapsed/refractory myelofibrosis (MF)

Meeting Abstract

El Chaer, F.; Rein, L.; Shimoda, K.; Yuda, J.; Haque, T.; McCloskey, J.; Takami, A.; Fukaya, M.; Shirane, S.; Kabir, S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Real-world (RW) outcomes with venetoclax (VEN) in patients with acute myeloid leukemia (AML) from COTA, a US RW evidence database

Meeting Abstract

Stein, E.; Hodzic, S.; Owusu, H.; Pathak, D.; Zhou, S.
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

The randomized Phase III SIERRA (Study of Iomab-B in Elderly relapsed or refractory AML) trial: Successful allogeneic hematopoietic stem cell transplantation using treatment with Iomab-B-led regimen for patients with active, relapsed or refractory AML with failed targeted therapies

Meeting Abstract

Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Abboud, C.; Koshy, N.; Stiff, P. J.; Tomlinson, B.; Abhyankar, S.; Foran, J. M.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Post hoc analysis of patient responses by T315I mutation status from the 3-year update of the optic trial: A dose-optimization study of 3 starting doses of ponatinib

Meeting Abstract

Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial

Meeting Abstract

Apperley, J.; Cortes, J.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M.; Lipton, J. H.; Lomaia, E.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Clonal hematopoiesis and risk of lethal prostate cancer: a prospective cohort study with long-term follow-up

Meeting Abstract

Stopsack, K. H.; Chan, I. C.; Schmidt, E.; Panchot, A.; McNulty, S.; Schreiber, N. A.; Zhang, Y. W.; Penney, K. L.; Berger, M. F.; Diaz, L. A.; more...
Cancer Prevention Research (2023)

Fulltext@MSK | Save

Impact of tumor metabolism on the microenvironment and response to immunotherapy

Meeting Abstract

Zappasodi, R.; Serganova, I.; Brunschvig, S.; Santhella, A.; Mane, M.; Vemuri, K.; Ijoma, J.; Kang, W.; Manovatodorova, K.; Koutcher, J.; more...
Cancer Science (2023)

Fulltext@MSK | Save

Racial and ethnic disparities in outcomes following hematopoietic stem cell transplant (HCT) in patients with severe combined immunodeficiency (SCID)

Meeting Abstract

Winestone, L.; Logan, B. R.; Liu, X.; Buckley, R. H.; O'Reilly, R. J.; Griffith, L. M.; Puck, J.; Dvorak, C. C.; Cowan, M. J.; Haddad, E.
Clinical Immunology (2023)

Fulltext@MSK | Save